- Home
- SYBT vs VERA Comparison
SYBT vs VERA Comparison
Compare SYBT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYBT | VERA |
|---|---|---|
| Founded | 1904 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.5B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SYBT | VERA |
|---|---|---|
| Price | $68.65 | $47.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $83.67 | $67.67 |
| AVG Volume (30 Days) | 185.7K | ★ 1.9M |
| Earning Date | 01-21-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ 26.16 | N/A |
| EPS | ★ 4.58 | N/A |
| Revenue | ★ $378,633,000.00 | N/A |
| Revenue This Year | $17.26 | N/A |
| Revenue Next Year | $5.29 | N/A |
| P/E Ratio | $14.91 | ★ N/A |
| Revenue Growth | ★ 14.11 | N/A |
| 52 Week Low | $60.75 | $18.53 |
| 52 Week High | $83.83 | $51.19 |
Technical Indicators
Market Signals| Indicator | SYBT | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 74.43 |
| Support Level | $67.57 | $40.38 |
| Resistance Level | $69.87 | $51.19 |
| Average True Range (ATR) | 1.52 | 3.37 |
| MACD | 0.24 | 0.56 |
| Stochastic Oscillator | 61.37 | 81.92 |
Price Performance
Historical ComparisonAbout SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.